Quadrivalent HPV vaccination after effective treatment of Anal Intraepithelial Neoplasia in HIV+ men
Phase of Trial: Phase IV
Latest Information Update: 19 Jul 2019
Price : $35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Anal intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- Acronyms VACCAIN-P
- 16 May 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 13 Mar 2018 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.